New academic collaboration will help to advance precision medicine efforts to deliver the right treatment to patients at the right time
PRINCETON, NJ – 2015年6月3日 – Certara®, the global biosimulation technology-enabled drug development consultancy, today announced that it is endowing a new three-year, full-time position – the Certara Lecturer in Precision Dosing – at the Manchester Pharmacy School, The University of Manchester, England. This lectureship is intended to advance teaching and research into individual dose optimization modeling, and to demonstrate its application to cancer, pediatric, and biologic therapies.
This new lecturer will work closely with the clinical pharmacy, clinical pharmacology, and quantitative proteomics research groups at The University of Manchester to raise the profile of precision dosing within the university’s precision medicine initiative. This staff member will also lead post-graduate modeling and simulation programs.
“Our work with global biopharm companies and regulatory agencies demonstrates the advantages of using biosimulation to answer precision dosing questions for specific cohorts such as pediatric or geriatric patients, women who are pregnant, or patients with co-morbidities,” said Certara Chief Executive Officer Edmundo Muniz, M.D., Ph.D. “Through this new academic collaboration with The University of Manchester, we expect to further the field and make precision dosing for all individuals a reality.”
“Precision medicine has the potential to improve dramatically the healthcare outcomes for individual patients around the world,” added Professor Kay Marshall B.Pharm., FRPharm.S., PhD., MBA, head of Manchester Pharmacy School. “We are delighted to have this opportunity to partner with Certara and help prepare our students for exciting pharmacometric careers by providing them with individual dose optimization modeling experience.”
This new lecturer will become a member of the Systems Pharmacology Group within Manchester Pharmacy School. The postholder will report to the Head of School and be mentored by Professor Amin Rostami, Pharm.D., Ph.D., professor of systems pharmacology at The University of Manchester, and Certara’s Chief Scientific Officer.
About The University of Manchester
The University of Manchester, a member of the prestigious Russell Group of British universities, is the largest and most popular university in the UK. It has 20 academic schools and hundreds of specialist research groups undertaking pioneering multi-disciplinary teaching and research of worldwide significance.
The University of Manchester is one of the country’s major research institutions, rated fifth in the UK in terms of ‘research power’ (REF 2014), and has had no fewer than 25 Nobel laureates either work or study there. The University had an annual income of £886 million in 2013/14. http://www.manchester.ac.uk
Certara is a global biosimulation technology-enabled drug development consultancy. Its customers include hundreds of biopharmaceutical companies around the globe, together with several regulatory agencies. Certara’s solutions, which span the discovery, preclinical and clinical stages of drug development, enable data-driven decisions, leading to more precisely designed trials with a reduced risk of failure and improved subject safety. For more information, visit www.certara.com.
Ellen Leinfuss, 609-216-9586
Chief Marketing Officer
Lisa Osborne, 206-992-5245
Rana Healthcare Solutions